
News|Articles|August 19, 2026
What Nurses Need to Know About FDA-Approved Iberdomide in Multiple Myeloma
Author(s)By ONN Staff
Fact checked by: Alex Biese
Oncology clinical trial nurse navigator Elise Curry, RN, breaks down the key clinical questions surrounding the FDA approval of oral iberdomide.
Advertisement
Advertisement
The FDA granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) combined with daratumumab and hyaluronidase-fihj and dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. This approval introduces the first approved cereblon E3 ligase modulator (CELMoD) agent, establishing a novel therapeutic class in the myeloma landscape.
Related to this article

After a run of 2026 oral SERD approvals, Erica L. Mayer, MD, MPH, discusses ESR1 testing and a possible adjuvant role for giredestrant.

Donna D. Catamero, ANP-BC, OCN, CCRC, says CAR T-cell and bispecific therapies have myeloma teams discussing cure, with nurses on the front line.

Erica L. Mayer, MD, MPH, explains what the all-oral giredestrant plus everolimus regimen asks of patients and oncology nurses between clinic visits.

The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.
Advertisement
Advertisement

